How well is the female population represented in clinical trials with infusion therapies for Parkinson's disease? A systematic review and metanalysis
European Journal of Neurology · 2025-01 · 32 (1)
DOI: 10.1111/ene.70024 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift European Journal of Neurology, online erschienen am 05.01.2025. Verfasst von Katarzyna Smilowska und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Regional Hospital, Sosnowiec, Poland. Hauptthemen laut MEDLINE: Parkinson Disease, Antiparkinson Agents. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Parkinson's disease (PD) is a neurodegenerative disorder affecting both sexes, but differences exist between male and female in clinical manifestations, functional impact of symptoms and hormonal influences. Therefore, representativeness of females in PD trials indirectly determines the external validity of the clinical research in this field.
Objective
To estimate the representativeness of female in infusion therapy trials for advanced PD.
Methods
PubMed and EMBASE databases were searched (1980 to September 2023), along with congress abstracts, to identify controlled clinical trials and large non‐controlled studies on infusion therapies in PD enrolling >100 patients. Random‐effect meta‐analysis was conducted to estimate mean pooled prevalence of females included in the studies. Subgroup analyses were conducted accordingly to study design and intervention.
Results
We included 15 studies (six studies on levodopa‐carbidopa intestinal gel, six on subcutaneous levodopa, two on subcutaneous apomorphine, and one on levodopa‐carbidopa‐entacapone intestinal gel). Sex was not a randomisation stratification factor in any of these studies. Only one study explored differences in the outcome estimated according to sex. Overall, the proportion of female included was 38% (95% CI:33%–43%; I 2 = 74%), without differences between studies assessing different type of interventions ( p = 0.72) or between study design ( p = 0.35). In two studies, females represented the majority of included patients.
Conclusion
Female with advanced PD are underrepresented in infusion therapy trials. Most trials have overlooked sex‐based biological differences that can impact clinical and functional outcomes, raising concerns about the generalizability of these findings to real‐world contexts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Regional Hospital, Sosnowiec, Poland.
- Department of Neurology, Unidade Local de Saúde de Santa Maria, Lisbon, Portugal.
- Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada.
- Department of Bioethics, Medical University of Warsaw, Warsaw, Poland.
- Clinic of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, Hannover, Germany.
- Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal.
ORCID-Profile: Katarzyna Smilowska, Vanessa Carvalho, Natalia Szejko, Elena Moro, Angelo Antonini
Zitieren
APA
Smilowska, K., Carvalho, V., Szejko, N., Costa, J., Moro, E., & Antonini, A. (2025). How well is the female population represented in clinical trials with infusion therapies for Parkinson's disease? A systematic review and metanalysis. European Journal of Neurology, 32(1). https://doi.org/10.1111/ene.70024
Vancouver
Smilowska K, Carvalho V, Szejko N, Costa J, Moro E, Antonini A. How well is the female population represented in clinical trials with infusion therapies for Parkinson's disease? A systematic review and metanalysis. European Journal of Neurology. 2025;32(1). doi:10.1111/ene.70024
BibTeX
@article{Smilowska2025,
author = {Smilowska, Katarzyna and Carvalho, Vanessa and Szejko, Natalia and Costa, João and Moro, Elena and Antonini, Angelo},
title = {How well is the female population represented in clinical trials with infusion therapies for Parkinson's disease? A systematic review and metanalysis},
journal = {European Journal of Neurology},
year = {2025},
volume = {32},
number = {1},
doi = {10.1111/ene.70024}
}
EUVIMED